Among other functions, the NK cells (natural killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot ...

NKGen Biotech's CEO will present Phase 1 clinical trial results for NK cell therapy in Alzheimer's at AD/PD™ 2025. NKGen Biotech, Inc. announced that its CEO, Dr. Paul Y. Song, will present at ...

A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells ...

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, accounts for about 75–85% of all liver cancer ...

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on ...

With a storied history in vaccine development, India's Bharat Biotech is shaking things up and answering the call of advanced ...

Cancer metastasis, the spread of cancer to organs, is a major cause of cancer-related deaths. Once cancer spreads to multiple ...

Two years after Neil Armstrong walked on the Moon, US president Richard Nixon declared a new frontier in American scientific ...

Cancer metastasis, the spread of cancer to organs, is a major cause of cancer-related deaths. Once cancer spreads to multiple ...

By eliminating CD3 dependency, this approach overcomes a critical limitation in TCR-based NK cell therapy development, delivering a scalable, clinically viable solution that accelerates therapeutic ...

GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first ...